PIM
DNTH icon

Platinum Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

Platinum Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,044
Closed -$930K – 135
2022
Q1 		$930K Hold
20,044
– – 0.03% 103
2021
Q4 		$1.42M Hold
20,044
– – 0.04% 104
2021
Q3 		$2.33M Hold
20,044
– – 0.07% 94
2021
Q2 		$3.14M Hold
20,044
– – 0.07% 79
2021
Q1 		$3.8M Sell
20,044
-2,402
-11% -$404K 0.08% 65
2020
Q4 		$2.82M Buy
22,446
+7,355
+49% +$834K 0.06% 75
2020
Q3 		$1.64M Hold
15,091
– – 0.04% 87
2020
Q2 		$1.81M Sell
15,091
-1,218
-7% -$172K 0.04% 90
2020
Q1 		$1.64M Buy
16,309
+3,307
+25% +$613K 0.04% 76
2019
Q4 		$3.15M Sell
13,002
-3,401
-21% -$636K 0.06% 53
2019
Q3 		$2.69M Buy
16,403
+2,243
+16% +$426K 0.06% 53
2019
Q2 		$3.34M Buy
14,160
+1,013
+8% +$250K 0.08% 48
2019
Q1 		$3.46M Sell
13,147
-1,167
-8% -$201K 0.08% 49
2018
Q4 		$1.3M Buy
14,314
+9,708
+211% +$1.32M 0.04% 68
2018
Q3 		$885K Buy
4,606
+1,481
+47% +$312K 0.03% 79
2018
Q2 		$675K Buy
+3,125
New +$705K 0.02% 79

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Platinum Investment Management's DNTH Position: Q2 2022 in Review

Platinum Investment Management sold out of Dianthus Therapeutics (DNTH) in Q2 2022, closing a stake of 20,044 shares — an estimated $930K sold.

Platinum Investment Management first reported a position in DNTH in Q2 2018 and held it in 16 quarters. The position peaked at $3.8M in Q1 2021. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

  • Platinum Investment Management reported no remaining Dianthus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Platinum Investment Management sold 20,044 Dianthus Therapeutics shares in Q2 2022, an estimated $930K.
  • Platinum Investment Management first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 16 quarters.
  • Platinum Investment Management's Dianthus Therapeutics position peaked at $3.8M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on Platinum Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.